Morgan Stanley resumed coverage on Zealand Pharma
$ZEAL
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley resumed coverage of Zealand Pharma with a rating of Equal-Weight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2024 | Buy | Berenberg | |
| 8/8/2023 | Equal-Weight | Morgan Stanley | |
| 11/16/2022 | Overweight → Equal-Weight | Morgan Stanley | |
| 1/11/2022 | Hold → Buy | Jefferies |
15F-12B - Zealand Pharma A/S (0001674988) (Filer)
S-8 POS - Zealand Pharma A/S (0001674988) (Filer)
S-8 POS - Zealand Pharma A/S (0001674988) (Filer)
Berenberg initiated coverage of Zealand Pharma with a rating of Buy
Morgan Stanley resumed coverage of Zealand Pharma with a rating of Equal-Weight
Morgan Stanley downgraded Zealand Pharma from Overweight to Equal-Weight
Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark's flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidatesAgreement will support Zealand Pharma's Metabolic Frontier 2030 strategy to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030 Copenhagen, Denmark, January 9, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming t
Press release – No. 1 / 2026 Zealand Pharma to present at the J.P. Morgan Healthcare Conference Copenhagen, Denmark, January 5, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the Company will participate in the 44th J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, California. Adam Steensberg, President and Chief Executive Officer, will take part in a presentation and fireside chat on Wednesday January 14 at 1:30pm PST / 10:30pm CET. A live audio webcast will be available at: https://jpmorgan.metameetings.net/events/healthcare2
Company announcement – No. 27 / 2025 Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 Copenhagen, Denmark, December 31, 2025 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred. In Company Announcement No. 25 / 2025 dated December 11, 2025, Zealand Pharma announced a share capital increase due to the exercise of employee war
Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Copenhagen, Denmark, September 24, 2025 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Rachel James-Owens as Vice President, Corporate Communications & Media Relations. Rachel brings over 20 years of global pharmaceutical experience across Pfizer and Novartis, spanning sales, commercial, and corporate and executive communications. Most recently, she served as Executive Director, Global Corporate Communications a
Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently appointed CSO Utpal Singh to strengthen Zealand Pharma's R&D leadership and progress its differentiated clinical pipeline of potential best-in-class peptide therapeutics Copenhagen, Denmark, May 19, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnolog
Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide medicines, investing in new technologies including data and computational science Utpal to expand the global scientific team to drive Zealand Pharma's next wave of highly differentiated, innovative therapies, building on the Company's strong drug development heritage Copenhagen, Denmark, 23 April 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)
Company announcement – No. 25 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78),), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 150,317 divided into 150,317 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma's incentive scheme. Each
Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and survodutide, upcoming Capital Markets Day will set the stage for a catalyst-rich 2026. Achieved key milestone in the petrelintide Phase 2 ZUPREME-1 trial in people with overweight and obesity, with the last participant completing the 28-week primary endpoint visit, paving the way for 42-week topline data in H1 2026.Approaching Phase 3 data in H1 2026 with survodutide, following last participant last visit in the 76-week SYNCHRONIZETM-1 trial in people with overweight and obes
Press Release – No. 15 / 2025 Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results Copenhagen, Denmark, November 6, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 13, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the third quarter of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David K
SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)
SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)